It looks like not only the old BLI tazobactam (approved in 1993) found new combinations, such as ceftolozane-tazobactam from Cubist, the new DABCO combinations are also getting approvals or progressing into clinical trials. AZ, Merck, and now Roche (Fedora) are all in the game, is this a renaissance of the long-lasting field? Personally, my medchem project started with BLI on the old tazo-type structure 20 years ago (BMCL, 1995, 5, 1513-18) and also recently I worked on DABCO series (WO2013150296). It's a truly unique class of enzymes to design inhibitors around.
No comments:
Post a Comment